Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genetron Health
Beijing, Beijing, Chinagenetronhealth.com ↗
- Ownership
- Private
- Employees
- ~700
- Development stage
- Commercial
01
Overview
Genetron Health has commercialized HCCscreen™, a blood-based NGS test for early detection of hepatocellular carcinoma in China and received FDA Breakthrough Device designation in the US. The company offers a comprehensive portfolio covering early screening, diagnosis, monitoring, and biopharma services. It has established long-term academic partnerships and collaborates with major global pharma/biotech companies. Clinical results have shown significant benefits in early detection and management of cancer patients.
- Therapeutic areas
- Oncology
- Modalities
- Next-generation sequencing (NGS)Molecular diagnosticsLiquid biopsy
- Industry
- Molecular Diagnostics
02
Partnerships
Beyond the preview
Go deeper on Genetron Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genetron Health.